{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:17:03Z","timestamp":1787167023686,"version":"build-2736575974"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,28]]},"DOI":"10.7759\/cureus.88905","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T13:50:39Z","timestamp":1753710639000},"source":"Crossref","is-referenced-by-count":1,"title":["Targeted Therapy in HER2 Exon 20-Mutant Non-small Cell Lung Cancer With Leptomeningeal Disease: A Case-Based Approach to Treatment Decision-Making"],"prefix":"10.7759","author":[{"given":"Osama","family":"Elzaafarany","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-1585","article-title":"Leptomeningeal metastasis from non-small cell lung cancer and current landscape of treatments","volume":"29","author":"Ozcan G","year":"2023","unstructured":"Ozcan G, Singh M, Vredenburgh JJ. Leptomeningeal metastasis from non-small cell lung cancer and current landscape of treatments. Clin Cancer Res. 2023, 29:11-29. 10.1158\/1078-0432.CCR-22-1585","journal-title":"Clin Cancer Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01361","article-title":"Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: primary results from the randomized, phase II DESTINY-Lung02 trial","volume":"41","author":"Goto K","year":"2023","unstructured":"Goto K, Goto Y, Kubo T, et al.. Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: primary results from the randomized, phase II DESTINY-Lung02 trial. J Clin Oncol. 2023, 41:4852-63. 10.1200\/JCO.23.01361","journal-title":"J Clin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac144","article-title":"Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: the DEBBRAH trial","volume":"25","author":"P\u00e9rez-Garc\u00eda JM","year":"2023","unstructured":"P\u00e9rez-Garc\u00eda JM, Vaz Batista M, Cortez P, et al.. Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: the DEBBRAH trial. Neuro Oncol. 2023, 25:157-66. 10.1093\/neuonc\/noac144","journal-title":"Neuro Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-023-00584-5","article-title":"Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and\/or leptomeningeal disease (ROSET-BM)","volume":"9","author":"Niikura N","year":"2023","unstructured":"Niikura N, Yamanaka T, Nomura H, et al.. Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and\/or leptomeningeal disease (ROSET-BM). NPJ Breast Cancer. 2023, 9:82. 10.1038\/s41523-023-00584-5","journal-title":"NPJ Breast Cancer"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-024-04788-y","article-title":"Durable responses to trastuzumab deruxtecan in patients with leptomeningeal metastases from breast cancer with variable HER2 expression","volume":"170","author":"Rogawski D","year":"2024","unstructured":"Rogawski D, Cao T, Ma Q, Roy-O'Reilly M, Yao L, Xu N, Nagpal S. Durable responses to trastuzumab deruxtecan in patients with leptomeningeal metastases from breast cancer with variable HER2 expression. J Neurooncol. 2024, 170:209-17. 10.1007\/s11060-024-04788-y","journal-title":"J Neurooncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.06.006","article-title":"Poziotinib for EGFR exon 20-mutant NSCLC: clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity","volume":"40","author":"Elamin YY","year":"2022","unstructured":"Elamin YY, Robichaux JP, Carter BW, et al.. Poziotinib for EGFR exon 20-mutant NSCLC: clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity. Cancer Cell. 2022, 40:754-67.e6. 10.1016\/j.ccell.2022.06.006","journal-title":"Cancer Cell"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.21037\/apm-21-213","article-title":"HER2 exon 20 insertion mutations in lung adenocarcinoma with leptomeningeal metastasis: a case report and response to poziotinib","volume":"11","author":"Fan Y","year":"2022","unstructured":"Fan Y, Qin J, Han N, Lu H. HER2 exon 20 insertion mutations in lung adenocarcinoma with leptomeningeal metastasis: a case report and response to poziotinib. Ann Palliat Med. 2022, 11:1582-8. 10.21037\/apm-21-213","journal-title":"Ann Palliat Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2503704","article-title":"Zongertinib in previously treated HER2-mutant non-small-cell lung cancer","volume":"392","author":"Heymach JV","year":"2025","unstructured":"Heymach JV, Ruiter G, Ahn MJ, et al.. Zongertinib in previously treated HER2-mutant non-small-cell lung cancer. N Engl J Med. 2025, 392:2321-33. 10.1056\/NEJMoa2503704","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13051120","article-title":"Structural basis for the functional changes by EGFR exon 20 insertion mutations","volume":"13","author":"Tamirat MZ","year":"2021","unstructured":"Tamirat MZ, Kurppa KJ, Elenius K, Johnson MS. Structural basis for the functional changes by EGFR exon 20 insertion mutations. Cancers (Basel). 2021, 13:1120. 10.3390\/cancers13051120","journal-title":"Cancers (Basel)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13143540","article-title":"Trastuzumab mechanism of action; 20 years of research to unravel a dilemma","volume":"13","author":"Maadi H","year":"2021","unstructured":"Maadi H, Soheilifar MH, Choi WS, Moshtaghian A, Wang Z. Trastuzumab mechanism of action; 20 years of research to unravel a dilemma. Cancers (Basel). 2021, 13:3540. 10.3390\/cancers13143540","journal-title":"Cancers (Basel)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/388150-targeted-therapy-in-her2-exon-20-mutant-non-small-cell-lung-cancer-with-leptomeningeal-disease-a-case-based-approach-to-treatment-decision-making","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T13:50:40Z","timestamp":1753710640000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/388150-targeted-therapy-in-her2-exon-20-mutant-non-small-cell-lung-cancer-with-leptomeningeal-disease-a-case-based-approach-to-treatment-decision-making"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.88905","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6925753\/v1","asserted-by":"object"}]},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,28]]}}}